Category: Present
-
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
•
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Feb 22, 2025 • 10 minute…
-
Levin, Sa’ar present judicial overhaul compromise
•
Justice Minister Yariv Levin and Foreign Minister Gideon Saar are promoting a new plan to change the composition of the Judicial Selection Committee. Under the plan, the committee will consist of three members of the ruling coalition (ministers and Knesset members), a member of the opposition, three judges, and two…
-
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lun
•
The first scientific presentation of previously announced data from Cohort 1 of an ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg twice daily) in IPF, confirms positive trends in seven of the eight biomarkers evaluated, suggesting to a potential therapeutic effect Enrollment in the second cohort evaluating high-dose…
-
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress By Investing.com
•
BOSTON–(BUSINESS WIRE)–Asteria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immune diseases, today announced that it will present preliminary data for nafinibart alfa-star at the upcoming European Academy of Dermatology & Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024. Dr.…
-
NMDP BioTherapies To Present Data at ISCT 2024 on the Stability of Infectious Disease Marker Analytes During Donor Qualification for Allogeneic Cell Therapies
•
Article content The study, jointly conducted by researchers from Labor Quade and Johns Hopkins University School of Medicine, analyzed the long-term stability of IDM analytes in non-centrifuged peripheral blood samples to allow for increased flexibility in processing donor samples. The study results indicate that the widespread use of blood processing…
-
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention By Investing.com
•
new Taipei city, May 11, 2024 /PRNewswire/ — Calliway Biopharmaceuticals (Calliway) is pleased to announce its partnership to share the latest clinical developments in the upcoming 2024 year Vital International Convention on Wednesday, June 5in 11:45 AM PT. The presentation will take place at Theater show company 2 in San…